The Human Aggregated Amyloid Beta ELISA quantitates Hu aggregated Aβ in human tissue homogenates, ventricular fluid, CSF, tissue culture supernatant, and buffered solution. The assay will exclusively recognize both natural and recombinant Hu aggregated Aβ.
Principle of the method
The Human aggregated Aβ solid-phase sandwich ELISA (enzyme-linked immunosorbent assay) is designed to measure the amount of the target bound between a matched antibody pair. A target-specific antibody has been pre-coated in the wells of the supplied microplate. Samples, standards, or controls are then added into these wells and bind to the immobilized (capture) antibody. The sandwich is formed by the addition of the second (detector) antibody, a substrate solution is added that reacts with the enzyme-antibody-target complex to produce measurable signal. The intensity of this signal is directly proportional to the concentration of target present in the original specimen.
Each manufactured lot of this ELISA kit is quality tested for criteria such as sensitivity, specificity, precision, and lot-to-lot consistency. See manual for more information on validation.
Beta-amyloid is a 40–43 amino acid peptide cleaved from amyloid precursor protein, and a putative gamma-secretase. Amyloid beta (1-40) together with Amyloid beta (1-42) are two major C-terminal variants of the amyloid beta protein, constituting the majority of amyloid beta proteins. Both the amyloid beta (40) and amyloid beta (42) alloforms are major components of the extracellular plaques found in Alzheimer's disease brain tissue.
For Research Use Only. Not for use in diagnostic procedures. Not for resale without express authorization.